Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
28. März 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024.
Arcutis to Report Third Quarter 2023 Financial Results
25. Oktober 2023 16:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis will host a conference call and webcast at 8:30 a.m. ET on 11/3/2023 to report its third quarter financial results and provide a business update.
Arcutis to Present at Upcoming Investor Conference
12. April 2023 16:45 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03. Februar 2023 16:10 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress
06. September 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in...
Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update
05. Mai 2022 16:01 ET
|
Arcutis Biotherapeutics, Inc.
Increasing commercial preparations in advance of our Prescription Drug User Fee Act (PDUFA) action date of July 29, 2022 for roflumilast cream for the treatment of plaque psoriasis in adults and...
Arcutis to Host Investor Day on March 28
21. März 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis to Present at Upcoming Investor Conference
02. März 2022 05:30 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
22. Februar 2022 16:01 ET
|
Arcutis Biotherapeutics, Inc.
Received U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis in adults and adolescentsCompleted enrollment...